Cannabis, Linked Emotions, and Adolescent Risk Study
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age12-18
SponsorMassachusetts General Hospital
About this trial
The goal of this study is to disentangle relationships between acute cannabis use and withdrawal on proximal depression and suicide risk and recovery in adolescents ages 12-18 years by incorporating time-varying patterns of substance use, mood, and SI. This project aims to guide the development of scalable, individualized, accessible, and affordable interventions aimed to reduce depression and suicide risk among adolescents.
Eligibility criteria
Qualifiers
Ages 12-18;
Current daily or near daily cannabis use (i.e., use ≥ 4 days per week on average; Timeline Followback);
Score ≥ 5 on PHQ-9;
Access to an internet-capable smartphone (iOS or Android);
Disqualifiers
Any factor that impairs ability to comprehend and effectively participate, including acute intoxication at time of consent;
Cannabis use >4 times/day on average (to maximize likelihood of capturing mood and SI during non-use times);
Inability to speak/write English fluently;
Gross cognitive impairment, for example due to florid psychosis, intellectual disability, developmental delay, or neurodegenerative disease;
Trial design
Treatments tested in this trial
- Contingency management for cannabis abstinence
Treatment groups
200 Participants
are divided into 3 treatment groupsSponsors and collaborators
Massachusetts General Hospital
Lead sponsor
National Institute on Drug Abuse (NIDA)
Collaborator
Source ClinicalTrials.gov